Safety
ADVERSE EVENTS
The safety population was used in the safety analyses. In the treatment group with SOC plus disulfiram and copper, there were significantly more patients with adverse events (AE) CTCAE grade 3 or higher (14 patients [34%] vs SOC group: 5 [11%]; 